Menu
Search
|

Menu

Close
X

ARCA Biopharma Inc ABIO.OQ (NASDAQ Stock Exchange Capital Market)

1.55 USD
-- (--)
As of Feb 22
chart
Previous Close 1.55
Open --
Volume --
3m Avg Volume 30,025
Today’s High --
Today’s Low --
52 Week High 2.75
52 Week Low 1.05
Shares Outstanding (mil) 12.97
Market Capitalization (mil) 19.46
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.455
FY16
-1.813
FY15
-2.256
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
1.03
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-82.09
14.43
Return on Equity (TTM)
vs sector
-82.23
16.13

EXECUTIVE LEADERSHIP

Robert Conway
Chairman of the Board, Since 2014
Salary: --
Bonus: --
Michael Bristow
President, Chief Executive Officer, Director, Since 2009
Salary: $279,564.00
Bonus: $21,100.00
Thomas Keuer
Chief Operating Officer, Since 2014
Salary: --
Bonus: --
Christopher Ozeroff
Senior Vice President, General Counsel, Secretary, Since 2009
Salary: $273,234.00
Bonus: $12,350.00
Brian Selby
Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11080 Circle Point Rd Ste 140
WESTMINSTER   CO   80020-2769

Phone: +1720.9402200
Site: arcabio.com/

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

SPONSORED STORIES